PT - JOURNAL ARTICLE AU - Castañeda-Sabogal, Alex AU - Chambergo-Michilot, Diego AU - Toro-Huamanchumo, Carlos J. AU - Silva-Rengifo, Christian AU - Gonzales-Zamora, José AU - Barboza, Joshuan J. TI - Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis AID - 10.1101/2021.01.26.21250420 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.26.21250420 4099 - http://medrxiv.org/content/early/2021/01/27/2021.01.26.21250420.short 4100 - http://medrxiv.org/content/early/2021/01/27/2021.01.26.21250420.full AB - Background To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19.Methods Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE.Results After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I2= 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence.Conclusions There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that they have no conflicts of interest. This study has not been funded by any institution.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was a systematic review, so no ethics committee review was required for approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll database access data for the systematic search are available in our supplementary material.